Topilutamide
Based on 1 publication(s) in Google Scholar
Topilutamide is a topical nonsteroidal antiandrogen (NSAA).
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.91%
- CAS. Nr.: 260980-89-0
- Formel: C13H11F6N3O5
- Molecular Weight:403.23
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Transcription Factor-Targeted Library
HY-L090
-
Anti-Prostate Cancer Compound Library
HY-L124
-
Nuclear Receptor Compound Library
HY-L126
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Anti-Cancer Compound Library
HY-L025
Publications Citing Use of MedChemExpress (MCE) Topilutamide
More
Biologische Aktivität
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 260980-89-0
-
Appearance Solid
-
Molecular Weight 403.23
-
Formel C13H11F6N3O5
-
Color White to off-white
-
SMILES
O=C(NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1)C(C)(O)CNC(C(F)(F)F)=O
-
Synonyms
BP766; Fluridil
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
BMC Cancer
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy. [Abstract]2023 Nov 13;23(1):1102. PMID: 37957639
Lösungsmittel & Löslichkeit
DMSO : 100 mg/mL (248.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.20 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (271 KB)
-
SDS (537 KB)
- English - EN (537 KB)
- Français - FR (537 KB)
- Deutsch - DE (537 KB)
- Norwegian - NO (537 KB)
- Español - ES (537 KB)
- Swedish - SV (537 KB)
- Italian - IT (537 KB)
- Korean - KR (537 KB)
- Portuguese - PT (537 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Suresh PS, et al. Review of HPLC and LC-MS/MS assays for the determination of various nonsteroidal anti-androgens used in the treatment of prostate cancer. Biomed Chromatogr. 2017 Jun 21. [Content Brief]
[2]. Sovak M, Seligson AL, Kucerova R, Bienova M, Hajduch M, Bucek M. Fluridil, a rationally designed topical agent for androgenetic alopecia: first clinical experience [published correction appears in Dermatol Surg 2002 Oct;28(8):following 970]. Dermatol Surg. 2002;28(8):678-685. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4800 mL | 12.3999 mL | 24.7997 mL | 61.9994 mL |
| 5 mM | 0.4960 mL | 2.4800 mL | 4.9599 mL | 12.3999 mL | |
| 10 mM | 0.2480 mL | 1.2400 mL | 2.4800 mL | 6.1999 mL | |
| 15 mM | 0.1653 mL | 0.8267 mL | 1.6533 mL | 4.1333 mL | |
| 20 mM | 0.1240 mL | 0.6200 mL | 1.2400 mL | 3.1000 mL | |
| 25 mM | 0.0992 mL | 0.4960 mL | 0.9920 mL | 2.4800 mL | |
| 30 mM | 0.0827 mL | 0.4133 mL | 0.8267 mL | 2.0666 mL | |
| 40 mM | 0.0620 mL | 0.3100 mL | 0.6200 mL | 1.5500 mL | |
| 50 mM | 0.0496 mL | 0.2480 mL | 0.4960 mL | 1.2400 mL | |
| 60 mM | 0.0413 mL | 0.2067 mL | 0.4133 mL | 1.0333 mL | |
| 80 mM | 0.0310 mL | 0.1550 mL | 0.3100 mL | 0.7750 mL | |
| 100 mM | 0.0248 mL | 0.1240 mL | 0.2480 mL | 0.6200 mL |
Topilutamide Related Classifications
HY-19470 Related Classifications
Powered by Bioz